0001157523-16-006777.txt : 20160926 0001157523-16-006777.hdr.sgml : 20160926 20160926154733 ACCESSION NUMBER: 0001157523-16-006777 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20160907 FILED AS OF DATE: 20160926 DATE AS OF CHANGE: 20160926 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aurinia Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001600620 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36421 FILM NUMBER: 161902215 BUSINESS ADDRESS: STREET 1: #1203-4464 MARKHAM STREET CITY: VICTORIA BC STATE: A1 ZIP: V8Z 7X8 BUSINESS PHONE: 250-708-4272 MAIL ADDRESS: STREET 1: #1203-4464 MARKHAM STREET CITY: VICTORIA BC STATE: A1 ZIP: V8Z 7X8 6-K 1 a51427725.htm AURINIA PHARMACEUTICALS 6-K


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

 REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934

Dated September 7, 2016

Commission File Number 001-36421

AURINIA PHARMACEUTICALS INC.
(Exact name of Registrant as specified in its charter)

N/A
(Translation of Registrant’s Name)

#1203-4464 Markham Street
Victoria, British Columbia
V8Z7X8
(250) 708-4272
(Address and telephone number of registrant’s principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  ⃞     Form 40-F  ⊠

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ⃞

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ⃞

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ⃞     No  ⊠

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated:

September 7, 2016

 

Aurinia Pharmaceuticals Inc.

 

 

 

By:

/s/ Michael R. Martin

 

Name:

Michael R. Martin

 

 

Title:

Chief Operating Officer

2

EXHIBIT INDEX

Exhibit

 

Description of Exhibit

 
99.1

News Release – Aurinia Pharmaceuticals to Present at the 2016 Rodman & Renshaw 18th Annual Global Investment Conference

3

EX-99.1 2 a51427725ex99_1.htm EXHIBIT 99.1

Exhibit 99.1

Aurinia Pharmaceuticals to Present at the 2016 Rodman & Renshaw 18th Annual Global Investment Conference

VICTORIA, British Columbia--(BUSINESS WIRE)--September 7, 2016--Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX:AUP) today announced that its Chief Operating Officer, Michael R. Martin, will present a corporate overview of the Company at the 2016 Rodman & Renshaw 18th Annual Global Investment Conference, taking place September 11th-13th at the Lotte New York Palace Hotel in New York City. The presentation will also be available via webcast at the link listed below.

Aurinia Presentation Details

Date:

 

Monday, September 12th, 2016

Time:

10:00 a.m. Eastern time

Location:

Lotte New York Palace Hotel, Louis Room (4th floor)

Webcast:

http://wsw.com/webcast/rrshq26/auph

About Aurinia
Aurinia is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is headquartered in Victoria, BC and focuses its development efforts globally.

Visit www.auriniapharma.com for more information.

CONTACT:
Investor & Media Contact:
Celia Economides
Associate VP, Investor Relations
ceconomides@auriniapharma.com